Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...
A subsidiary of a Miami-based company is inching closer to FDA approval for a drug that treats a rare pediatric disease.
Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...
By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and ...
Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...
The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for ...
The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...
COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed ...
About Numiera Therapeutics Numiera is a preclinical-stage pharmaceutical company focused on developing small-molecule ...
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...